PepSets™ Peptide Libraries ❭

PepSets™ can be supplied with a precise length and offset designed to best suit the user’s assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence to adapt the usage for any experimental purpose.

In recent years, PepSets™ have had tremendous successes in the immunology sector for vaccine and drug development. These versatile molecular tools have further applications in dozens of fields, including epitope mapping and structure-activity studies.  

  • Discover crucial residues with an Alanine Scan Library 
  • Map epitopes with an Overlapping Peptide Library 
  • Narrow down the shortest active sequences with a Truncated Peptide Library

Fast & Reliable

Mimotopes is the founder of peptide libraries. Across the 35 years since its inception, the technology and its userbase have developed side-by-side to make PepSets™ an unrivaled juggernaut in research today.

Hundreds of peptides are synthesized simultaneously with Mimotopes’ exclusive parallel synthesis technology. Thanks to a rapid production cycle, peptide libraries reach their users fast, aiming to never delay critical experiments.

Contact us today for a quote!

Australia

☎ +61 3 9565 1111
✉ australia@mimotopes.com

North and South America

☎ +1 651 603 0909
✉ useast@mimotopes.com
uswest@mimotopes.com

Asia

☎ +61 3 9565 1111
✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547
✉ europe@mimotopes.com

Go to article: Home | Inside the world of priority review vouchers where time is moneyGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Lactalis IngredientsGo to article: In DepthGo to article: Inside the world of priority review vouchers where time is money Go to article: Quality and sustainability: The balancing act for pharma manufacturingGo to article: 2023 in review: Cancer vaccines dose up on advances with tailored approachesGo to article: Diversity and ePROs: Still siloed concepts in the era of DCTs? Go to article: Q&A: Tackling the rise of fake anti-obesity drugs on the market Go to article: Patching the problem of EU drug shortagesGo to article: Out-of-spec cell therapy manufacturing: an ethical dilemma for CDMOs and doctorsGo to article: NiproGo to article: phasetwoGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: Foreword: What’s next for the Internet of ThingsGo to article: An introduction to the Internet of Things Go to article: The digital ecosystem of the IoTGo to article: Timeline: Internet of ThingsGo to article: The impact of IoT on the pharma industry Go to article: Applications of IoT in the pharma industryGo to article: Latest news: IoT in pharmaGo to article: Analyst Q&A: IoT in pharmaGo to article: Bupa leverages unique position to develop IoT and AI features Go to article: IoT innovation: Leading companies in microneedles for transdermal drug deliveryGo to article: IoT in the pharmaceutical industry: analysing innovation, investment and hiring trendsGo to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: Avenga Company InsightGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue